Difficulty: Medium
Average Score: 88%
Practice
This is a drug of choice for acute treatment of ventricular tachycardias:
Correct answer
C
Rationale
In the context of advanced pharmacology across the lifespan, the correct answer to the question regarding the drug of choice for acute treatment of ventricular tachycardias is option C) Lidocaine.
Lidocaine is the preferred choice for ventricular tachycardias due to its fast onset of action and effectiveness in stabilizing the cardiac membrane, making it particularly useful in managing ventricular arrhythmias. It acts by blocking sodium channels, thus decreasing depolarization and reducing the automaticity of ventricular tissue.
Option A) Flecainide is contraindicated in the presence of structural heart disease due to its proarrhythmic effects and potential to exacerbate ventricular arrhythmias. Option B) Sotalol, while effective in certain arrhythmias, is not the first-line choice for acute treatment of ventricular tachycardias. Option D) Verapamil is a calcium channel blocker and is contraindicated in ventricular tachycardias as it can worsen these arrhythmias by depressing myocardial contractility.
Understanding the rationale behind the choice of Lidocaine for ventricular tachycardias is crucial for healthcare providers managing cardiac emergencies. It highlights the importance of selecting the appropriate antiarrhythmic agent based on the underlying mechanism of action and the specific arrhythmia being treated to ensure optimal patient outcomes.
Lidocaine is the preferred choice for ventricular tachycardias due to its fast onset of action and effectiveness in stabilizing the cardiac membrane, making it particularly useful in managing ventricular arrhythmias. It acts by blocking sodium channels, thus decreasing depolarization and reducing the automaticity of ventricular tissue.
Option A) Flecainide is contraindicated in the presence of structural heart disease due to its proarrhythmic effects and potential to exacerbate ventricular arrhythmias. Option B) Sotalol, while effective in certain arrhythmias, is not the first-line choice for acute treatment of ventricular tachycardias. Option D) Verapamil is a calcium channel blocker and is contraindicated in ventricular tachycardias as it can worsen these arrhythmias by depressing myocardial contractility.
Understanding the rationale behind the choice of Lidocaine for ventricular tachycardias is crucial for healthcare providers managing cardiac emergencies. It highlights the importance of selecting the appropriate antiarrhythmic agent based on the underlying mechanism of action and the specific arrhythmia being treated to ensure optimal patient outcomes.